CCR10 and neoplasm: However, we note that CCR10’s off-tumor expression profile is comparable to other clinically-investigated myeloma CAR-T targets SLAMF7 and CD138 (Supplementary Fig. 11A–C), and therefore is not anticipated to be particularly unfavorable.